Search clinical trials for: Proteinase Inhibitory Proteins, Secretory

Total 14858 results

Nanjing Medical University
Beijing Anzhen Hospital

Completed

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II

Acute Aortic Syndrome | Type A Aortic Dissection

China
Indiana University

Completed

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding ((RAMBLE))

Venous Thromboembolism | Menstruation

United States
Bayer
Janssen Research & Development, LLC

Completed

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban) (FARAONIC)

Heart Failure

Spain
Brigham and Women's Hospital

Completed

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism | Pulmonary Embolism | DVT

United States
Bayer

Completed

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

Treatment of Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Venous Thromboembolism

Japan
Alan Bryce

Unknown

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)

Severe Acute Respiratory Syndrome

United States
Daiichi Sankyo Co., Ltd.

Completed

Study of DU-176b Aged 80 Years or Older

Atrial Fibrillation

Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (XANTUS-EL)

Atrial Fibrillation

Colombia, Kazakhstan, Mexico, Russian Federation, Argentina, Azerbaijan, Bahrain, Chile, Egypt, Georgia, Jordan, Kenya, Lebanon, Saudi Arabia, United Arab Emirates, Uruguay, Venezuela
Konkuk University Medical Center

Completed

Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass

Cardiac Surgery | Cardiopulmonary Bypass

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (NEURO-XAR)

Stroke | Embolism

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (SOPRANO)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Russian Federation
Bayer
Janssen Scientific Affairs, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (SAFARI)

Atrial Fibrillation

France
Centre Hospitalier Universitaire de Nīmes

Completed

Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention (Naco_Nîmes)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (X-TRA)

Atrial Fibrillation

France, Germany, Turkey, Russian Federation, Bulgaria, Ukraine, Poland
Bristol-Myers Squibb
Pfizer

Completed

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Healthy Volunteers

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

Therapeutic Equivalency

Germany
Bristol-Myers Squibb
Pfizer

Completed

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Venous Thrombosis

Australia, Czech Republic, India, Italy, Korea, Republic of, Mexico, United Kingdom, United States, Hong Kong, Spain, France, Argentina, Brazil, Russian Federation, Austria, Denmark, Germany, Israel, Portugal, Romania, Singapore, ... and more
Astellas Pharma Inc

Completed

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Venous Thromboembolism

Japan
Huazhong University of Science and Technology

Not yet recruiting

Effect of Ulinastatin on the Action of NDMRs (Rocuronium / Cisatracurium)

Nondepolarising Muscle Relaxants

China
Ottawa Hospital Research Institute

Recruiting

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters (TRIM-Line)

Cancer | Venous Thromboembolism

Canada
Anthos Therapeutics, Inc.
The TIMI Study Group; Fortrea

Active, not recruiting

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

Stroke | Atrial Fibrillation (AF)

United States, Canada, Czechia, Hungary, Korea, Republic of, Poland, Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Medical University of South Carolina
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

Chronic Pancreatitis

United States
Thomas Kander

Completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Bleeding | Trauma | Hypothermia | Acidosis

Sweden
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Brazilian Clinical Research Institute
Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Hospital do Coracao and other collaborators

Terminated

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 (APOLLO)

Covid19 | Thrombosis

Brazil
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Johns Hopkins University
Bristol-Myers Squibb

Completed

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

Kidney Failure, Chronic | Venous Thromboembolic Disease

United States
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Bayer
Janssen Research & Development, LLC

Completed

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Thromboembolic Disorders

Germany
Bayer
Janssen Research & Development, LLC

Completed

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Thrombosis

Canada, United States, Belgium, Spain, Italy, France, Finland, Hungary
Bayer
Janssen Research & Development, LLC

Completed

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (EINSTEINJr)

Venous Thromboembolism

Switzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (XANAP)

Atrial Fibrillation

Indonesia, Korea, Republic of, Malaysia, Singapore, Thailand, Philippines, Taiwan, Hong Kong, India, Pakistan, Vietnam
Bayer
Janssen Research & Development, LLC

Completed

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (HEROIC)

Atrial Fibrillation

Spain
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)

Venous Thrombosis

Belgium
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Venous Thrombosis | Pediatrics

Italy, United States, Austria, Australia, Canada, France, Switzerland, Germany, Israel, Ireland
The University of Texas Health Science Center,...

Completed

Argatroban Stroke Treatment - A Pilot Safety Study

Ischemic Stroke

United States
Danone North America

Completed

Comparison of Plant and Animal Proteins on Amino Acid Concentrations

Healthy Resistance-Trained Males

Canada
Kyowa Kirin Co., Ltd.
Japan Blood Products Organization

Completed

KW-3357 Study in Patients With Early Onset Severe Preeclampsia

Preeclampsia

Japan
Han Yaling, MD

Completed

Reduce Bolus Injection of Bivalirudin

Acute Coronary Syndrome

China
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Terminated

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

Lung Cancer

United States
Boehringer Ingelheim

Completed

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Atrial Fibrillation

United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, Malaysia, Netherlands, Norway, Phili... and more
SK Chemicals Co., Ltd.
Korea University Anam Hospital

Completed

Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III

Healthy

Korea, Republic of
The Medicines Company

Completed

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

Myocardial Infarction

United States
University Children's Hospital, Zurich

Recruiting

Short and Long-arm Fiberglass Cast Immobilization for Distal Salter Harris I and II Forearm Fractures in Children

Fracture Forearm

Switzerland
Intermountain Health Care, Inc.
Boehringer Ingelheim

Completed

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF)

Dementia | Cognition Disorders | Cerebral Ischemic Events

United States
Medical University of South Carolina
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Interstitial Lung Disease | Scleroderma

United States

Search clinical trials for: Proteinase Inhibitory Proteins, Secretory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations